If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV
50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How is Reyvow® (lasmiditan) metabolized and eliminated?
Reyvow (lasmiditan) undergoes hepatic and extrahepatic metabolism primarily by non-cytochrome P450 enzymes. Recovery of unchanged lasmiditan in urine was low and accounted for approximately 3% of the dose.
Lasmiditan undergoes hepatic and extrahepatic metabolism primarily by non-cytochrome P450 enzymes.1
The following enzymes are not involved in metabolism of lasmiditan, including
- monoamine oxidase-A
- monoamine oxidase-B
- flavin monooxygenase 3
- cytochrome P450 reductase
- xanthine oxidase
- alcohol dehydrogenase
- aldehyde dehydrogenase, and
- aldo-keto reductases.1
Major metabolites of lasmiditan identified in plasma and urine are
- S-M8, through ketone reduction to alcohol (major pathway)
- M7, through oxidation on piperidine ring, and
- M18, through a combination of M7 and M8 pathways.1
Relative to lasmiditan, these metabolites are considered pharmacologically inactive.1
Lasmiditan is primarily eliminated via metabolism.1
Renal excretion is a minor route of lasmiditan clearance with approximately 3% of the dose recovered as unchanged lasmiditan in urine. Metabolite S-M8 represented approximately 66% of the dose in urine, with the majority of recovery within 48 hours post dose.1
Enclosed Prescribing Information
1Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: August 12, 2021